Výsledky vyhledávání

Akademický článek

Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder

Autor: Lam RW, Lamy FX, Danchenko N, Yarlas A, White MK, Rive B, Saragoussi D

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2861-2877 (2018)

Raymond W Lam,1 François-Xavier Lamy,2 Natalya Danchenko,2 Aaron Yarlas,3 Michelle K White,3 Benoît Rive,2 Delphine Saragoussi2 1Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; 2Global Outcomes Research, Lundbeck SA

Externí odkaz: https://doaj.org/article/45dbf74a0fb44b6ba80e448a18196b27

Zobrazit plný text záznamu

An adaptive design for early drug development including interim decision for single-arm trial with external controls or randomized trial

Autor: Götte, H, Kirchner, M, Krisam, J, Allignol, A, Lamy, FX, Schüler, A, Kieser, M

Publikováno v: 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS); 20200906-20200909; Berlin; DOCAbstr. 226 /20210226/

Background: In early clinical development, where only few drug candidates have the potential for market approval, the gold standard, a randomized controlled trial (RCT) might not be the most efficient option for ethical and economic reasons. The requ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985aa00f63633b8f8e7e26ccee939ef3

Zobrazit plný text záznamu

Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study

Autor: Haro JM, Lamy FX, Jönsson B, Knapp M, Brignone M, Caillou H, Chalem Y, Hammer-Helmich L, Rive B, Saragoussi D

Publikováno v: BMC Psychiatry
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

BACKGROUND: Patients who require a switch in their antidepressant therapy may have different clinical profiles and treatment needs compared with patients initiating or maintaining a first-line antidepressant therapy. METHODS: The Prospective Epidemio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::082d1837e0434eb9dcc295f0d1c6cbe0
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14084

Zobrazit plný text záznamu

Akademický článek

Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis.

Autor: Lamy, FX., Chollet, J., Clay, E., Brignone, M., Rive, B., Saragoussi, D.

Publikováno v: Current Medical Research & Opinion; Apr2015, Vol. 31 Issue 4, p795-807, 13p

Zobrazit plný text záznamu

Report

Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.

Autor: Kasper S; West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Germany. Electronic address: stefan.kasper@uk-essen.de., Foch C; Merck Healthcare KGaA, Darmstadt, Germany., Esser R; Merck Healthcare KGaA, Darmstadt, Germany., Lamy FX; Merck Healthcare KGaA, Darmstadt, Germany., Zhang A; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China., Cheng AL; National Taiwan University Cancer Center, Taipei, Taiwan., Rouyer M; Bordeaux PharmacoEpi, INSERM CIC1401, University of Bordeaux, Bordeaux, France., Brodowicz T; Internal Medicine, Vienna General Hospital and Medical University of Vienna, Austria., Zielinski C; Comprehensive Cancer Centre, Vienna General Hospital and Medical University of Vienna, Austria.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Feb; Vol. 180, pp. 85-88. Date of Electronic Publication: 2022 Nov 26.

Zobrazit plný text záznamu

Akademický článek

Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.

Autor: Cosgrove DP; Compass Oncology, The US Oncology Network, Vancouver, Washington, USA., Reese ES; EMD Serono, Billerica, Massachusetts, USA., Fulcher NM; Ontada, The Woodlands, Texas, USA., Bobiak SS; EMD Serono, Billerica, Massachusetts, USA., Lamy FX; Healthcare Business of Merck KGaA, Darmstadt, Germany., Allignol A; Healthcare Business of Merck KGaA, Darmstadt, Germany., Boyd M; Ontada, The Woodlands, Texas, USA., Mahmoudpour SH; Healthcare Business of Merck KGaA, Darmstadt, Germany.

Publikováno v: Cancer medicine [Cancer Med] 2023 Feb; Vol. 12 (4), pp. 4195-4205. Date of Electronic Publication: 2022 Oct 20.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.

Autor: Beachler DC; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA., Lamy FX; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany., Kolitsopoulos F; Global Medical Epidemiology, Pfizer, New York, NY 10017, USA., Dinh J; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA., Papazian A; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA., Jamal-Allial A; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA., Mahmoudpour SH; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany., Michelon E; Safety Surveillance & Risk Management, Pfizer, New York, NY 10017, USA., Verpillat P; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Aug; Vol. 18 (26), pp. 2891-2901. Date of Electronic Publication: 2022 Jul 18.

Zobrazit plný text záznamu

Akademický článek

Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety.

Autor: Khankhel ZS; PRECISIONheor, Boston, MA 02110, USA., Goring S; SMG Outcomes Research, Vancouver, BC, V6T0C2, Canada., Bobiak S; EMD Serono Research & Development Institute, Inc., Billerica, MA 01821, USA, an affiliate of Merck KGaA., Lamy FX; Merck Healthcare KGaA, Darmstadt, 64293, Germany., Nayak D; PRECISIONheor, New York, NY 10018, USA., Garside J; GlaxoSmithKline, Brentford, TW8 9GS, UK., Reese ES; EMD Serono Research & Development Institute, Inc., Billerica, MA 01821, USA, an affiliate of Merck KGaA., Schoenherr N; Merck Healthcare KGaA, Darmstadt, 64293, Germany.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Jun; Vol. 18 (18), pp. 2321-2338. Date of Electronic Publication: 2022 Apr 07.

Zobrazit plný text záznamu

Akademický článek

An adaptive design for early clinical development including interim decision for single-arm trial with external controls or randomized trial.

Autor: Götte H; Global Biostatistics, Epidemiology & Medical Writing, Merck Healthcare KGaA, Darmstadt, Germany., Kirchner M; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany., Krisam J; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany., Allignol A; Global Biostatistics, Epidemiology & Medical Writing, Merck Healthcare KGaA, Darmstadt, Germany., Lamy FX; Global Biostatistics, Epidemiology & Medical Writing, Merck Healthcare KGaA, Darmstadt, Germany., Schüler A; Global Biostatistics, Epidemiology & Medical Writing, Merck Healthcare KGaA, Darmstadt, Germany., Kieser M; Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany.

Publikováno v: Pharmaceutical statistics [Pharm Stat] 2022 May; Vol. 21 (3), pp. 625-640. Date of Electronic Publication: 2022 Jan 21.

Zobrazit plný text záznamu

Akademický článek

Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.

Autor: Zhang X; EMD Serono, Billerica, MA., Beachler DC; HealthCore Inc., Wilmington, DE., Masters E; Pfizer, New York, NY., Liu F; EMD Serono, Rockland, MA., Yang M; EMD Serono, Rockland, MA., Dinh J; HealthCore Inc., Wilmington, DE., Jamal-Allial A; HealthCore Inc., Wilmington, DE., Kolitsopoulos F; Pfizer, New York, NY., Lamy FX; the healthcare business of Merck KGaA, Darmstadt, Germany.

Publikováno v: Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2022 Feb; Vol. 28 (2), pp. 255-265. Date of Electronic Publication: 2021 Dec 02.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání